128
Participants
Start Date
June 22, 2023
Primary Completion Date
February 29, 2024
Study Completion Date
February 29, 2024
RSVpreF 120 µg
RSVpreF standard dose level
RSVpreF 60 µg
RSVpreF low dose level
Rochester Clinical Research, LLC, Rochester
Duke Vaccine And Trials Unit, Durham
Bio-Medical Research LLC, Miami
University of Alabama at Birmingham - School of Medicine, Birmingham
Senders Pediatrics, South Euclid
Cincinnati Children's Hospital Medical Center, Cincinnati
Velocity Clinical Research, Sioux City, Sioux City
Velocity Clinical Research, Omaha, Omaha
Velocity Clinical Research, New Orleans, Metairie
Innovo Research - Austin Regional Clinic, Austin
Velocity Clinical Research, Austin, Austin
Velocity Clinical Research, Salt Lake City, West Jordan
Peninsula Research Associates, Rolling Hills Estates
Stanford University Medical Center, Palo Alto
Seattle Children's - Building Cure, Seattle
Seattle Children's Hospital, Seattle
Velocity Clinical Research, Providence, East Greenwich
Lead Sponsor
Pfizer
INDUSTRY